Spyre Therapeutics to Participate in Several Investor Conferences in September

WALTHAM, Mass., Sept. 03, 2026 /CourierPR/ -- Spyre Therapeutics, a clinical-stage biotechnology company focused on developing next-generation immunology therapies, will participate in several upcoming investor conferences in September 2026.

The company’s management team will be present at the Citi 2026 BioPharma Back to School Conference in New York on September 9 at 10:00 am Eastern Time. The team will also attend the Wells Fargo 21st Annual Healthcare Conference in Boston on September 10, where they will host a fireside chat at 8:00 am Eastern Time. Additionally, members of Spyre’s management will present at the Stifel 2026 Virtual Immunology and Inflammation Forum on September 23 at 8:30 am Eastern Time.

During these events, Spyre will host one-on-one meetings with investors. Live audio webcasts and replays of the events will be available on the company’s investor events website at <https://ir.spyre.com/events-and-presentations>.

Spyre Therapeutics is dedicated to advancing immunology through the development of next-generation therapies that offer more complete disease control, greater durability, and a simpler treatment experience for patients. The company’s pipeline includes investigational extended half-life antibodies targeting α4β7, TL1A, IL-23, and IL-17A/F, as well as rational combination programs.

Attendees of the conferences can expect to hear more about Spyre’s innovative approaches and the potential impact of its therapies on the field of immunology.